Joseph W Polli - JoVE Visualize

Showing results (31-40 of 51) with videos related to

Pageof 6

Sort By:

BMC Pharmacology & Toxicology|May 15, 2013

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusAnita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 30, 2005

Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1Maciej J Zamek-Gliszczynski, Keith A Hoffmaster, Xianbin Tian, et al.

Clinical Pharmacology and Therapeutics|May 15, 2018

Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter ConsortiumRaymond Evers, Micheline Piquette-Miller, Joseph W Polli, et al.

Pharmacology|August 28, 2004

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein bindingKelly M Mahar Doan, Stephen A Wring, Larry J Shampine, et al.

Journal of Pharmaceutical Sciences|July 2, 2009

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministrationKimberly K Adkison, Soniya S Vaidya, Daniel Y Lee, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 19, 2004

The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transportersJoseph W Polli, Todd M Baughman, Joan E Humphreys, et al.

Therapeutic Advances in Infectious Disease|December 18, 2023

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirineParul Patel, Paula Teichner, Emilie Elliot, et al.

Clinical Pharmacology and Therapeutics|May 25, 2022

Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium PerspectiveKunal S Taskar, Xinning Yang, Sibylle Neuhoff, et al.

The Journal of Infectious Diseases|July 25, 2024

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine TrialsEmilie R Elliot, Joseph W Polli, Parul Patel, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 2, 2012

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studiesJames F Sigafoos, Gary D Bowers, Stephen Castellino, et al.

Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:

Pageof 6

BMC Pharmacology & Toxicology|May 15, 2013

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusAnita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 30, 2005

Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1Maciej J Zamek-Gliszczynski, Keith A Hoffmaster, Xianbin Tian, et al.

Clinical Pharmacology and Therapeutics|May 15, 2018

Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter ConsortiumRaymond Evers, Micheline Piquette-Miller, Joseph W Polli, et al.

Pharmacology|August 28, 2004

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein bindingKelly M Mahar Doan, Stephen A Wring, Larry J Shampine, et al.

Journal of Pharmaceutical Sciences|July 2, 2009

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministrationKimberly K Adkison, Soniya S Vaidya, Daniel Y Lee, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 19, 2004

The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transportersJoseph W Polli, Todd M Baughman, Joan E Humphreys, et al.

Therapeutic Advances in Infectious Disease|December 18, 2023

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirineParul Patel, Paula Teichner, Emilie Elliot, et al.

Clinical Pharmacology and Therapeutics|May 25, 2022

Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium PerspectiveKunal S Taskar, Xinning Yang, Sibylle Neuhoff, et al.

The Journal of Infectious Diseases|July 25, 2024

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine TrialsEmilie R Elliot, Joseph W Polli, Parul Patel, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 2, 2012

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studiesJames F Sigafoos, Gary D Bowers, Stephen Castellino, et al.

Pageof 6